Form 4: Quest Diagnostics CFO Sam Samad Increases Equity Stake

Quest Diagnostics CFO Sam Samad acquired 108 shares of common stock through a dividend reinvestment plan.

Summary

• Sam Samad, Executive Vice President and CFO of Quest Diagnostics, acquired 108 shares of common stock.
• The transaction occurred on April 20, 2026, at a price of $194.698 per share.
• The acquisition was executed via a dividend reinvestment plan.
• Following this transaction, the reporting person holds a total of 33,376 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the acquisition is a routine dividend reinvestment rather than an open-market purchase.

Positives

• The CFO is increasing their direct equity stake in the company, signaling confidence in long-term value.

Negatives

• None identified; this is a routine transaction related to dividend reinvestment.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that routine dividend reinvestment by C-suite executives is a standard practice that typically reflects passive participation in corporate benefit programs rather than a strategic market signal.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and equity management practices observed in large-cap healthcare companies like LabCorp or HCA Healthcare.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard dividend reinvestment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Dividend Reinvestment, CFO